← ANALYST RATINGS · TIPRANKS
Atrium Therapeutics, Inc. (RNA): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $25.00, the highest $25.00, the lowest $25.00. The average is +225.9% from the last price of $7.67.
Analyst ratings 6
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $7.00−6.7% | Sell | −8.7% | Reiterated | 17.10.26on TipRanks 09:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.50−6.2% | Hold | −2.2% | Reiterated | 15.10.26on TipRanks Oct 14 21:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $7.50−6.2% | Sell | −2.2% | Downgrade | 15.10.26on TipRanks Oct 14 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.50−6.2% | Hold | −2.2% | Reiterated | 15.10.26on TipRanks Oct 14 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $7.50−6.2% | Hold | −2.2% | Upgrade | 15.10.26on TipRanks Oct 14 21:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $7.50−6.2% | Hold | −2.2% | Upgrade | 15.10.26on TipRanks Oct 14 21:05 | — | |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $25.00 | Buy | +225.9% | Reiterated | 14.10.26on TipRanks Oct 15 07:55 | +0.2%next day +1.5% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $7.50−6.2% | Sell | −2.2% | Reiterated | 13.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $8.00+6.7% | Sell | +4.3% | Downgrade | 10.10.26on TipRanks Oct 9 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $8.00+6.7% | Hold | +4.3% | Reiterated | 10.10.26on TipRanks Oct 9 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $8.00+6.7% | Hold | +4.3% | Upgrade | 10.10.26on TipRanks Oct 9 21:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $8.00+6.7% | Sell | +4.3% | Reiterated | 10.10.26on TipRanks Oct 9 21:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $8.00+6.7% | Hold | +4.3% | Upgrade | 10.10.26on TipRanks Oct 9 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.50−6.2% | Hold | −2.2% | Reiterated | 08.10.26on TipRanks 17:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $8.00+6.7% | Hold | +4.3% | Reiterated | 06.10.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $8.00+6.7% | Hold | +4.3% | Reiterated | 06.10.26on TipRanks 12:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.50−6.2% | Hold | −2.2% | Reiterated | 04.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.50−6.2% | Hold | −2.2% | Reiterated | 04.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $7.50−6.2% | Hold | −2.2% | Upgrade | 04.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $7.50−6.2% | Hold | −2.2% | Upgrade | 04.10.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $7.50−6.2% | Sell | −2.2% | Downgrade | 03.10.26on TipRanks Oct 2 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $7.50−6.2% | Sell | −2.2% | Reiterated | 03.10.26on TipRanks Oct 2 23:05 | — | |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $25.00 | Buy | +225.9% | Reiterated | 02.10.26on TipRanks Oct 5 07:56 | −4.4%next day +1.0% · 5 days +6.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.50 → $8.00−5.9% | Hold | +4.3% | Reiterated | 02.10.26on TipRanks Oct 1 21:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.50 | Hold | +10.8% | Reiterated | 30.09.26on TipRanks 20:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 | Sell | +4.3% | Downgrade | 30.09.26on TipRanks 20:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 | Hold | +4.3% | Reiterated | 30.09.26on TipRanks 20:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 | Hold | +4.3% | Upgrade | 30.09.26on TipRanks 20:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 | Sell | +4.3% | Reiterated | 30.09.26on TipRanks 20:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 | Hold | +4.3% | Upgrade | 30.09.26on TipRanks 20:05 | — | |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $25.00 | Buy | +225.9% | Reiterated | 14.08.26on TipRanks 06:55 | +4.3%next day +1.4% · 5 days +4.2% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $25.00 | Buy | +225.9% | Reiterated | 14.08.26on TipRanks Aug 13 13:10 | +0.6%next day +4.3% · 5 days +11.3% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $25.00 | Buy | +225.9% | Reiterated | 13.08.26on TipRanks Aug 17 05:56 | +0.6%next day +4.3% · 5 days +11.3% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $25.00 | Buy | +225.9% | Initiated | 15.05.26on TipRanks 10:45 | +0.9%next day −2.0% · 5 days −1.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Atrium Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $25.00 at a price of $8.28 (+201.9%); now: $25.00 at $7.67 (+225.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 6 | 5 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Atrium Therapeutics, Inc.
- CEO: Kathleen Gallagher
- Employees: 511
- 10578 Science Center Drive, San Diego, CA, 92121, US
- www.atriumtherapeutics.com
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Data from the stock’s TipRanks forecast page, read 79 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗